Bladder Cancer: FDA Expands Anktiva Without a New Trial

On October 14, 2026, the FDA expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) that has not responded to BCG.1 The approval, granted to Altor BioScience, makes Anktiva the first FDA-approved treatment specifically for this group of patients.

For drug developers, how the agency reached its decision matters as much as the decision itself.1 The FDA did not require a dedicated trial in papillary-only disease. Instead, it relied on the evidence behind Anktiva's earlier approval in carcinoma in situ (CIS), with or without papillary tumors, along with the scientific similarities between the two forms of the disease.

“We listen to patients, clinicians, and researchers, and we act when the science supports a new approach,” said R. Angelo de Claro, M.D., Director of the FDA's Oncology Center of Excellence. “For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with CIS and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments.”

What Evidence Supported the Expanded Indication?

The CIS approval was based on a trial (NCT03022825) of 77 adults, some of whom also had papillary tumors. Sixty-two percent achieved a complete response, meaning no high-grade cancer was detected during follow-up. Of those responders, 58% maintained the response for at least 12 months and 40% for at least 24 months.

For the expansion, FDA considered those results alongside clinical and laboratory evidence that CIS and high-grade papillary tumors often occur together, can be hard to tell apart under a microscope, and carry a high risk of recurrence or progression once BCG stops working. CIS forms flat patches along the bladder lining and is always high-grade. Papillary tumors grow as finger-like projections and can be either low- or high-grade.

Anktiva and BCG are instilled into the bladder through a catheter once a week for six weeks. Further treatment depends on response and can continue for up to 37 months. Common adverse events included frequent or painful urination, urgency, blood in the urine, urinary tract infections, muscle or joint pain, chills, fever, and elevated creatinine and potassium. The prescribing information warns that delaying surgery to remove the bladder can allow the cancer to spread, which can be fatal.

Why Does this Matter for Drug Development and Manufacturing?

The approval shows that FDA is willing to extend efficacy findings across closely related disease subtypes when the biology supports it. For sponsors in BCG-unresponsive NMIBC, that could mean shorter development timelines and smaller trial programs. The agency said it is working toward finalizing its draft guidance, “Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment,” which is expected to address using CIS data to support approvals in papillary-only disease. That framework builds on guidance that, as PharmTech reported in 2016, first set out FDA's expectations for diagnosis and staging, risk stratification, and trial design and endpoints in this setting.

For manufacturing and supply chain teams, label expansions granted without a new pivotal study can increase demand faster than a traditional development cycle would. Anktiva's own history shows how much approval depends on manufacturing readiness. Its original application was turned down in 2023 after FDA found deficiencies during pre-license inspections of the developer's third-party contract manufacturers, and the agency also raised additional chemistry, manufacturing, and controls questions. Because the product is co-administered with BCG, supply of both components matters. The developer previously secured an additional BCG source through a partnership with the Serum Institute of India.

As FDA finalizes its guidance, developers of intravesical and immune-based therapies will be watching closely. The agency's openness to bridging evidence across related indications is likely to shape both clinical strategy and commercial supply planning.

What Does the Dosing Schedule Mean for Supply Planning?

The recommended dose is 400 mcg, instilled with BCG once a week for six weeks as induction therapy. Patients with residual CIS or high-grade Ta tumors at month 3 may receive a second induction course. Maintenance consists of three weekly instillations at months 4, 7, 10, 13, and 19, for a total of 15 doses. Patients with no high-grade disease at month 25 may receive up to nine more instillations at months 25, 31, and 37. Because the regimen is long and depends on response, demand per patient can vary widely. That makes forecasting for both Anktiva and BCG harder as the eligible population grows.

References

1. U.S. Food and Drug Administration. FDA approves first treatment for certain people with BCG-unresponsive bladder cancer. October 14, 2026. Accessed October 16, 2026. View source

2. U.S. Food and Drug Administration. FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. October 14, 2026. Accessed October 16, 2026. View source